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S302 Poster Session IResults: Sixteen of 17 evaluable patients have engrafted (one is too
early to evaluate). Early toxicity data is available for 16 patients
and include: oral mucositis (maximum grade 3), hypertension (max-
imum grade 3), and hyperbilirubinemia (N5 3). One patient devel-
oped hepatic veno-occlusive disease, after which the busulfan goal
level on pharmacokinetic analysis was reduced to keep a lower steady
state concentration target. After this adjustment, there have been no
further occurrences of VOD. Infections included: CMV viremia
(N 5 2), influenza A (N 5 1), clostridium difficile (N 5 1), bacter-
emia (N 5 1) and clostridium botulinum (N 5 1). To date, 14 of
the 17 patients are alive and disease-free at a median follow up of 6
months (range 0.3 – 28months). Cause of death for the three patients
was multi-organ failure (N 5 1), infection (N 5 1), and severe pul-
monary hypertension (N 5 1).
Table 1. Patient and donor characteristics
Characteristics Number or Median (Range)Table 1.
Patients tested (n)
Overall prevalence (n;%) 23/63 (3
Viremia only (n;%) 5/63 (8
Invasive disease (n;%) 6/63 (1
Stoll only (n;%) 11/63 (1
Median viral load (copies/ml) 2,189 (6Patients
Total no. of patients 17
Males 9
Females 8
Age (years) 8 (5-27)
Transplant indication
Severe Single lineage cytopenia 2
Aplastic anemia 12
MDS - refractory anemia 2
refractory anemia with excess blasts 1
Prior treatments
Transfusions 16
Androgens 8
Prior infections 6
Donors
Related 5
(parental 8/8, 6/8, 5/8 (N 5 2) and 4/8
matched donors)
Unrelated 12
(8/8 matched n5 11 and 7/8 matched N5 1)Conclusion: In this interim study report, engraftment, early toxicity
and infection data appear to be similar to historical TBI-based pro-
tocols with no graft failures to date. Although the study is ongoing
with planned accrual of 25 total patients, these results appear prom-
ising and suggest that such alternative donor HSCT can be effec-
tively performed without radiation.
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VIRAL INFECTIONS IN CHILDREN UNDERGOING AUTOLOGOUS HEMATO-
POIETIC STEM CELL TRANSPLANTATION
Ozdemir, N., Grimley, M.S., Davies, S.M., Myers, K.C., Mehta, P.A.,
Bleesing, J.J., Jordan, M.B., Marsh, R.A., Kumar, A.R.,
Filipovich, A.H., Jodele, S. Cincinnati Children’s Hospital Medical Cen-
ter, Cincinnati, OH
Background: Viral infections are a known cause of morbidity and
mortality in patients receiving allogenic hematopoietic stem cell
transplantation (SCT), however limited data has been reported in
pediatric patients undergoing autologous transplant. The aim of
this retrospective study was to evaluate the prevalence and outcomeAD V CM
63 63
5%) 6/63 (10%
%) 3/63 (5%)
0%) 3/63 (5%)
7%) 0
45-142,300) 15,567 (2,66of viral infections in children undergoing autologous SCT
(auto-SCT).
Methods: Between January 2004 and July 2011 a total of 140 autol-
ogous transplants were performed for malignant diseases in 90
patients. Patients who were seropositive for cytomegalovirus
(CMV) or Epstein-Barr virus (EBV) were monitored with blood
polymerase chain reaction (PCR) weekly. Adenovirus (ADV) weekly
blood monitoring by PCR was initiated in 2007. Polyoma BK virus
(BKV) virus testing was done as clinically indicated for hematuria
and if positive, monitoring for viremia was initiated. Viremia was de-
fined as the presence of virus in blood above detectable level on quan-
titative PCR. Invasive disease was defined as virus detection at least
in two different organ systems. Patients with hypogammaglobulin-
emia received intravenous immunoglobulin supplementation to
maintain nornal for age IGG level.
Results: Sixty four of 90 patients were tested for viruses. Twenty
nine of the tested patients had viruses detected, with 10 patients hav-
ing more than one virus. Table 1 summarizes the prevalence of vi-
remia and viral infections. Most prevelant virus was adenovirus,
presenting as either enteritis or invasive disease. CMV or EBV
pneumonitis was diagnosed in 3 symptomatic patients. Three pa-
tients developed virus-associated thrombotic microangiopathy re-
sulting in renal failure in 2 patients. Viral infection was a cause of
death in 2% (2/90) of all patients undergoing auto-SCT or in 3%
(2/64) of patients who were tested for viruses.
Conclusion: In our patient cohort serious viral infections were rare.
Even in the presence of invasive disease mortality was low. Data sug-
gests that routine viral screening is not neccesary for all patients un-
dergoing auto-SCT, however symptomatic patients should be
evaluated promptly.265
FAMILIAL HAPLOIDENTICAL (FHI) T-CELL DEPLETED (TCD) TRANS-
PLANTATION IN HIGH-RISK SICKLE CELL DISEASE (IND 14359)
Radhakrishnan, K.1, Talano, J.-A.2, Keever-Taylor, C.2, Bhatia, M.3,
Shenoy, S.4, Walters, M.5, Parsons, S.6, Morris, E.1, Baxter-
Lowe, L.A.7, Cairo, M.S.1 1New York Medical College, Valhalla, NY;
2Medical College of Wisconsin, Milwaukee, WI; 3Columbia University,
New York, NY; 4Washington University, St. Louis, MO; 5Children’s
Hospital & Research Center, Oakland, CA; 6TuftsMedical Center, Boston,
MA; 7University of California at San Francisco, San Francisco, CA
Background: Stem cell transplantation has been highly successful
for poor-risk SCD but only 14-18% of patients have an HLA-
matched unaffected sibling (Bhatia/Walters, BMT, 2008). Alternate
allogeneic donors include unrelated adult donors and unrelated cord
blood donors (Cairo et al., BBMT, 2008). Due to patient demo-
graphics matched unrelated adult donors are limited in the registries
and results of unrelated UCB transplants have been dismal to date.
(Bhatia/Cairo et al., ASBMT, 2010 and CTN 0601)
FHI TCD AlloSCT is an alternative that could greatly improve
outcomes in these patients. A recent phase II trial in high-risk leuke-
mia patients utilized CliniMACS (Miltenyi Biotec) one step CD34+
selection, and demonstrated a median recovery of CD34+ cells of
79%, median T-cell depletion of 4.5log, 94/101 patients engrafted
with aGVHD in only 8/100 patients. (Aversa et al.,JCO, 2005) Min-
imal-intensity conditioning followed by FHI TCD in high risk thal-
assemia patients achieved engraftment in 16/22 patients without
aGVHD and 90% OS. (Sodani et al., Blood, 2010)
Objective: This study seeks to employ a similar approach in high-
risk SCD patients.V EBV BK
58 5
) 9/58 (16%) 2/5 (40%)
6/58 (10%) 0
2/58 (3%) 2/5 (40%)
1/58 (2%) 0
5-61,600) 1,302 (647-7,207) 125,540 (50,520-44x10^6)
Table 1. Organizational Schema of Consortium
Clinical Sites/PIs External DSMC Scientific Advisory Committee Cores
NYMC:Mitchell S. Cairo, MD Michael Nieder, MD All Children’s
Hospital
Guido Lucarelli, MD University
of Tor Vergata
Donor Chimerism: LeeAnn
Baxter-Lowe, PhD (UCSF)
CHRCO:Mark Walters, MD Russell E. Ware, MD, PhD Baylor
College of Medicine
Adrian P. Gee, PhD Baylor
College of Medicine
Health Related Quality of Life: Susan
Parsons, MD (Tufts)
MCW: Julie-An Talano, MD Rupert Handgretinger, MD
Eberhard Karls Universit€at
T€ubingen
George Buchanan, MD
UT Southwestern
Neurocognition: Elizabeth Kera, PhD
(NYMC)
CUMC: Monica Bhatia, MD Daniel Heitjan, PhD UPenn Neuroimaging: Robert McKinstry, MD, PhD
(WashU)
Wash U: Shalini Shenoy, MD Pulmonary Function: Allen Dozor, MD
(NYMC)
Cell Processing Core Pulmonary Vascular Core: Deborah
Friedman, MD (NYMC) Rajamma
Mathew, MBBS (NYMC)
MCW: Carolyn Keever-Taylor, PhD;
WashU: Brenda Grossman, MD;
CUMC: Joseph Schwartz,MD;
Progenitor Cell Therapy:
Robert Preti, PhD
Immunology: NYMC: Mitchell S. Cairo, MD;
MCW: James Verbsky, MD, PhD, Jack
Gorski, PhD, and Carolyn Keever-Taylor, PhD
Radiation Therapy: R. Chitti, MD (NYMC)
Poster Session I S303Methods: Patients 2-20.99 years of age and who meet SCURT eli-
gibility without an 8/8 HLA matched unrelated donor will be en-
rolled. Patients will receive hydroxyurea (60mg/kg/day) and
azathioprine (3mg/kg/day) from days-59 to -11. Fludarabine
(30mg/m2) will be given for 6 days (day -17 to -13), busulfan
(4mg/kg/day) for 4 days (day -12 to -9) and cyclophosphamide for
4 days (day -7 to -4), thiotepa (10mg/kg, day -8), R-ATG (day -5
to -2), TLI (500cGy) followed by FHI T-cell depleted AlloSCT.
GVHD prophylaxis will consist of tacrolimus. HPC, Apheresis-
CD34-enriched cells will be collected by the CliniMACS (FDA
IND14359) with a target dose of 10.0 x 106 CD34+ cells/kg contain-
ing 2.0 x 105 CD3+ T cells/kg.
Results:Wehave developed a FHITCDConsortium of five clinical
sites, four processing centers, and cores in donor chimerism,
anti-HLA antibodies, immunology, cell processing, biostatistics,
neuroimaging, neurocognition, quality of life, pulmonary function,
pulmonary vascular, radiation, and a patient advocacy group
(www.haploscdconsortium.org) (Table 1).
Conclusion:We seek to develop a unique opportunity for high-risk
SCD patients to be cured of this debilitating disease, potentially im-
proving organ function, quality of life, and neurocognition while
providing a universal allogeneic donor source for many more at-
risk SCD patients.266
EPSTEIN-BARR VIRUS-RELATED POST-TRANSPLANT LYMPHOPROLIFER-
ATIVE DISORDER IN CHILDREN TREATED WITH RITUXIMAB: THE IM-
PACT OF VIRAL LOAD AND NON-LYMPHOID TISSUE INVOLVEMENT
Styczynski, J.1, Gil, L.2, Ljungman, P.3, Donnelly, J.P.4, Martino, R.5,
Theunissen, K.6, Maertens, J.6, Kalwak, K.7, Hubacek, P.8, Sica, S.9,
van der Velden, W.4, Omar, H.3, Nozzoli, C.10, Fagioli, F.11,
Matthes, S.12, Diaz, M.A.13, Migliavacca, M.14, Balduzzi, A.14,
Faraci, M.15, Tomaszewska, A.16, de la Camara, R.17, Hoek, J.18,
Einsele, H.19, Cesaro, S.20,21 1CollegiumMedicum UMK, Bydgoszcz, Po-
land; 2Medical University, Poznan, Poland; 3Karolinska University,
Stockholm, Sweden; 4University Medical Centre, Nijmegen, Netherlands;
5Hospital Santa Creu i Sant Pau, Barcelona, Spain; 6University Hospital,
Leuven, Belgium; 7Medical University, Wroclaw, Poland; 8University
Hospital Motol, Prague, Czech Republic; 9Universita Cattolica S. Cuore,
Rome, Italy; 10Ospedale di Careggi, Firenze, Italy; 11Onco-Ematologia
Pediatrica, Torino, Italy; 12St Anna Kinderspital, Vienna, Austria;
13Nino Jesus Children’s Hospital, Madrid, Spain; 14Ospedale San Ger-
ardo, Monza, Italy; 15 Institute G. Gaslini, Genova, Italy; 16 Institute of
Haematology and Blood Transfusion, Warsaw, Poland; 17Hospital de laPrincesa, Madrid, Spain; 18EBMT Study Office, Leiden, Netherlands;
19Julius Maximilian University, W€urzburg, Germany; 20Clinica di On-
coematologia Pediatrica, Padua, Italy; 21Policlinico G.B. Rossi, Verona,
Italy
Background: EBV-PTLD is a life threatening complication after
allo-HSCT. No risk factor analysis for outcome of PTLD therapy
has been reported so far. OBJECTIVE: Analysis of the risk factors
influencing the outcome of rituximab-based treatment of EBV-
PTLD after allo-HSCT in children.
Patients and Methods: PTLD was diagnosed in 55 (2.7%) cases of
the 2050 children given an allo-HSCT; biopsy-proven in 28 (50.5%)
cases or probable disease (lymphadenopathy with serumEBV-DNA-
emia) in the remainder. The median age at transplant was 7.8 years
(range, 0.3-16.8). Seven cases developed in HLA-identical siblings
(MFD), 7 in mismatched family/haplo, 23 in MUD and 18 in
MMUD. The source of stem cells: 32 PB, 18 BM and 5 CB. Patients
were treated weekly with a median of 3 doses of rituximab (range,
1-16) and with median of 375 mg/m2 per dose. Early response and
failure after therapy were defined by 1-log decrease and 1-log in-
crease, respectively, of EBV-DNA load at 1 week after the first
dose of rituximab.
Results:The incidence of EBV-PTLD ranged from 0.9% inMFD-
HSCT, 1.6% in MMFD/haplo-HSCT, 3.5% in MUD-HSCT, to
7.6% inMMUD-HSCT, and 3.1% in CBT) and developed in a me-
dian of 2 months (range, 0.2-81) after allo-HSCT. Resolution of
PTLD after rituximab therapy was observed in 43 (78%) cases.
The initial risk factors influencing outcome of PTLD therapy
were: EBV serology positive donor and recipient (HR 5 5, p 5
0.032), involvement of extra-lymphoid tissue (HR 5 9, p 5 0.037),
initial plasma EBV-DNA load .10^5 gc/mL (HR 5 8.3, p 5
0.002) but after multivariate analysis only involvement of extra-lym-
phoid tissue (HR5 9, p5 0.041) and initial plasma EBV-DNA load
.10^5 gc/mL (HR 5 7.7, p 5 0.003) remained significant. The re-
sponse to therapy, determined by .1 log decrease of EBV-DNA
load after 1 week of therapy (HR 5 0.17, p 5 0.015) and reduction
of immunosuppression contributed to better outcome (HR 5 0.23,
p 5 0.059) whereas an increase of EBV-DNA load during therapy
by .1 log (HR 5 8, p 5 0.004) corresponded to a worse outcome.
Reduction of immunosuppression possibly contributed to better sur-
vival from PTLD (HR 5 0.23, p 5 0.059).
Conclusions: Overall 78% of children with EBV-PTLD after allo-
HSCT responded to treatment with rituximab and early response
after 1 week of therapy correspondedwith a good prognosis. Involve-
ment of extra-lymphoid tissue, initial plasmaEBV-DNA load.10^5
gc/mL and increase of EBV-DNA load during therapy by 1 log were
predictors of poor outcome.
